| Species |
Human |
| Protein Construction |
CD84/SLAMF5 (Lys22-Gly225)
Accession # Q9UIB8-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
25.4 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5 B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. |
| Synonyms |
Hly9-beta; CD84; SLAMF5; LY9B; CD84 molecule; DKFZp781E2378;Hly9-β |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
